[{"id":"428cac7f-133f-43b4-8121-71893e06b7fb","acronym":"","url":"https://clinicaltrials.gov/study/NCT02498912","created_at":"2021-01-18T12:03:05.635Z","updated_at":"2025-02-25T14:35:42.787Z","phase":"Phase 1","brief_title":"Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors","source_id_and_acronym":"NCT02498912","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" PD-L1","pipe":" | ","alterations":" MUC16 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MUC16 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • JCAR020 • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 08/01/2015","start_date":" 08/01/2015","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2024-07-31"},{"id":"93901ec6-cb53-4006-986c-b326980ea647","acronym":"","url":"https://clinicaltrials.gov/study/NCT04501770","created_at":"2021-01-18T21:33:47.632Z","updated_at":"2024-07-02T16:36:26.942Z","phase":"Phase 1","brief_title":"A Study of M802 (HER2 and CD3) in HER2-Positive Advanced Solid Tumors","source_id_and_acronym":"NCT04501770","lead_sponsor":"Wuhan YZY Biopharma Co., Ltd.","biomarkers":" CEACAM5 • MUC16 • CA 19-9","pipe":" | ","alterations":" HER-2 positive • HER-2 expression • CEACAM5 expression • MUC16 expression","tags":["CEACAM5 • MUC16 • CA 19-9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 expression • CEACAM5 expression • MUC16 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e M802"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 08/28/2021","start_date":" 08/28/2021","primary_txt":" Primary completion: 11/30/2023","primary_completion_date":" 11/30/2023","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2021-08-04"},{"id":"07b4179f-e8ed-4410-a9f7-220b1ee391d8","acronym":"","url":"https://clinicaltrials.gov/study/NCT04501744","created_at":"2021-01-18T21:33:47.040Z","updated_at":"2024-07-02T16:36:42.300Z","phase":"Phase 1","brief_title":"A Study of M701 (EpCAM and CD3) in Malignant Ascites","source_id_and_acronym":"NCT04501744","lead_sponsor":"Wuhan YZY Biopharma Co., Ltd.","biomarkers":" CEACAM5 • MUC16 • AFP • CA 19-9","pipe":" | ","alterations":" CEACAM5 expression • MUC16 expression","tags":["CEACAM5 • MUC16 • AFP • CA 19-9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CEACAM5 expression • MUC16 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e M701"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 10/30/2018","start_date":" 10/30/2018","primary_txt":" Primary completion: 01/31/2021","primary_completion_date":" 01/31/2021","study_txt":" Completion: 06/30/2021","study_completion_date":" 06/30/2021","last_update_posted":"2020-08-06"},{"id":"53fe0544-7678-4017-9d25-016a8b99ae73","acronym":"","url":"https://clinicaltrials.gov/study/NCT04145947","created_at":"2021-01-18T20:15:29.764Z","updated_at":"2024-07-02T16:36:53.613Z","phase":"","brief_title":"Evaluation of Prognostic Monitoring for Triple Negative Breast Cancer Patients","source_id_and_acronym":"NCT04145947","lead_sponsor":"Peking Union Medical College Hospital","biomarkers":" MUC16","pipe":" | ","alterations":" MUC16 expression","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MUC16 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 04/25/2019","start_date":" 04/25/2019","primary_txt":" Primary completion: 03/01/2020","primary_completion_date":" 03/01/2020","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2019-11-18"},{"id":"7f318fb5-92b5-49fb-998a-0a583be9277a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04145960","created_at":"2021-01-18T20:15:29.979Z","updated_at":"2024-07-02T16:36:53.524Z","phase":"","brief_title":"Evaluation of Prognostic Monitoring for Women Who Have Completed Standard Treatment for Breast Cancer","source_id_and_acronym":"NCT04145960","lead_sponsor":"Peking Union Medical College Hospital","biomarkers":" MUC16","pipe":" | ","alterations":" MUC16 expression","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MUC16 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 04/25/2019","start_date":" 04/25/2019","primary_txt":" Primary completion: 03/01/2020","primary_completion_date":" 03/01/2020","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2019-11-18"},{"id":"8c600811-bf0b-496d-af50-5ffd5c480f5c","acronym":"","url":"https://clinicaltrials.gov/study/NCT04145986","created_at":"2021-01-18T20:18:55.486Z","updated_at":"2024-07-02T16:36:53.516Z","phase":"","brief_title":"Evaluation of Prognostic Monitoring for Young Breast Cancer Patients","source_id_and_acronym":"NCT04145986","lead_sponsor":"Peking Union Medical College Hospital","biomarkers":" MUC16","pipe":" | ","alterations":" MUC16 expression","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MUC16 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 04/25/2019","start_date":" 04/25/2019","primary_txt":" Primary completion: 03/01/2020","primary_completion_date":" 03/01/2020","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2019-11-18"},{"id":"c55e6560-824c-46e7-a036-c411c396c412","acronym":"","url":"https://clinicaltrials.gov/study/NCT04145973","created_at":"2021-01-18T20:15:30.192Z","updated_at":"2024-07-02T16:36:53.618Z","phase":"","brief_title":"Evaluation of Prognostic Monitoring for Breast Cancer Patients With Recurrence and Metastasis After Surgery","source_id_and_acronym":"NCT04145973","lead_sponsor":"Peking Union Medical College Hospital","biomarkers":" MUC16","pipe":" | ","alterations":" MUC16 expression","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MUC16 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 04/01/2019","start_date":" 04/01/2019","primary_txt":" Primary completion: 03/01/2020","primary_completion_date":" 03/01/2020","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2019-11-18"},{"id":"0f922648-2605-4a12-9b33-08b5a5febdbe","acronym":"","url":"https://clinicaltrials.gov/study/NCT02146313","created_at":"2021-01-18T09:58:27.690Z","updated_at":"2024-07-02T16:37:09.655Z","phase":"Phase 1","brief_title":"A Study Evaluating the Safety and Pharmacokinetics of DMUC4064A in Participants With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer","source_id_and_acronym":"NCT02146313","lead_sponsor":"Genentech, Inc.","biomarkers":" MUC16 • MUC4","pipe":" | ","alterations":" MUC16 expression","tags":["MUC16 • MUC4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MUC16 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RG7882"],"overall_status":"Completed","enrollment":" Enrollment 35","initiation":"Initiation: 06/22/2014","start_date":" 06/22/2014","primary_txt":" Primary completion: 06/18/2018","primary_completion_date":" 06/18/2018","study_txt":" Completion: 06/18/2018","study_completion_date":" 06/18/2018","last_update_posted":"2018-06-21"}]